Stanford researchers have developed a personalized arrhythmia risk prediction tool for dilated cardiomyopathy (DCM) patients using patient-derived induced pluripotent stem cells (iPSCs) to replicate heart biology and accurately predict arrhythmia risk, enabling timely interven